nevro - search results
If you're not happy with the results, please do another search
Nevro announces new data demonstrating health economic benefits of 10kHz SCS therapy
Nevro Corporation has announced the publication of new data validating the health economic benefits of 10kHz therapy, the company’s proprietary, high-frequency spinal cord stimulation...
Nevro announces full US market launch of HFX iQ spinal cord stimulation system
Nevro Corporation announced today that it has now initiated the full US market launch of its HFX iQ spinal cord stimulation (SCS) system, following...
Nevro announces US FDA approval of HFX iQ system to personalise chronic pain treatment
Nevro Corporation has announced that it has received approval from the US Food and Drug Administration (FDA) for the Senza HFX iQ spinal cord stimulation (SCS)...
Nevro announces publication of 12-month data on high-frequency SCS for non-surgical refractory back pain
Nevro Corporation has announced online publication of 12-month data from the SENZA-NSRBP randomised controlled trial (RCT) in Journal of Neurosurgery: Spine. These data show that...
Nevro announces clinical data reinforcing significant and durable benefits of 10kHz SCS therapy
Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...
Nevro announces FDA approval of high-frequency SCS therapy for painful diabetic neuropathy
Nevro has announced receipt of US Food and Drug Administration (FDA) approval for its Senza system to treat chronic pain associated with painful diabetic...
Nevro receives US FDA approval for Senza Omnia spinal cord stimulation system
Nevro has received approval from the US Food and Drug Administration (FDA) for the Senza Omnia spinal cord stimulation system to treat chronic pain....
Nevro receives TGA approval for Senza II spinal cord stimulation system delivering HF10 therapy
The Therapeutic Goods Administration (TGA) has granted approval to Nevro for its next-generation Senza II spinal cord stimulation system delivering the company’s proprietary HF10...
Nevro receives expanded MR-conditional labelling for Senza system in Europe and Australia
Senza is the first implantable spinal cord stimulator system that is 3 Tesla MRI-compatible.
Nevro receives FDA approvable letter for Senza spinal cord stimulation system
According to the approvable letter, approval of the PMA is subject to satisfaction of regulatory inspections and audits of manufacturing facilities, methods and controls for Senza.
Education and collaboration key to continued advancement of painful diabetic neuropathy care
The neuromodulation space has proliferated significantly over the past few years, and one area in which this is most notable is with the expansion...
High-frequency SCS demonstrates “substantial improvement” in health-related quality of life outcomes
Nevro Corporation has announced that the complete 12-month results from the SENZA-PDN randomised controlled trial (RCT), including health-related quality of life outcomes in patients with...
High responder rates, substantial pain relief and no explants among key 24-month SENZA-PDN data
Nevro Corporation has announced the results from data presentations at the American Diabetes Association (ADA) 82nd Scientific Sessions (3–7 June 2022, New Orleans, USA) supporting the use of...
High-frequency SCS drives impactful outcomes for non-surgical refractory back pain patients
Following the recent introduction of key data supporting the use of high-frequency spinal cord stimulation (SCS) in the treatment of non-surgical refractory back pain...
Spinal News International’s top 10 most popular stories of February 2022
Anterior lumbar interbody fusion versus transforaminal lumbar interbody fusion for treating those with isthmic spondylolisthesis was our top story in February, closely followed by...
Spinal News International’s top 10 most popular stories of November 2021
Research presented at the Global Spine Congress annual meeting (3–6 November 2021, Paris, France), a video on the effects of Covid-19 on spine care...
High-frequency SCS takes the stage to relieve chronic pain from diabetic neuropathy
Following the recent approval of the Senza system (Nevro) by the US Food and Drug Administration (FDA), Erika A Petersen (Little Rock, USA) discusses the...
Michael Enxing appointed Vertiflex vice president, chief commercial officer
Michael Enxing has been appointed as vice president and chief commercial officer of Vertiflex.
Enxing will be responsible for leading the company’s sales, marketing,...
Novel spinal neuromodulation device relieves pain in low back pain patients
After six months of using the Nevro system device in 30 patients, the average back and leg pain visual analog scores fell to 1.6 from eight and six (out of ten) respectively, according to researchers from the Guy's & St Thomas' Hospital, London, UK.
